Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1812 in Dementia with Lewy Bodies
NCT05225415Phase 2Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- May 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zervimesine in dementia with Lewy bodies (DLB), sponsored by Cognition Therapeutics, Inc.. Started May 2022; status: completed.
02
Drugs
zervimesine
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT05225415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225415.